Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly & Co., (NYSE: LLY) to provide AI drug discovery services. The deal, valued at up to USD 250 million in total upfront and milestone payments, will involve XtalPi leveraging its AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target.
XtalPi’s Industry-Leading AI and Robotics Platform
XtalPi is a quantum physics-based, AI-powered drug R&D company that has become an industry leader in combining mutually informative AI “dry lab” algorithms with large-scale “wet lab” robotics to empower pharmaceutical innovation. The firm’s ID4Inno small-molecule drug discovery platform applies AI, autonomous labs, and expert domain knowledge to generate and investigate a target-specific mega chemical space and identify promising lead series. Groups of synthesized molecules are tested using XtalPi’s internal biochemical, cellular, pharmacodynamic, and pharmacokinetic assay capabilities, applying generative AI models in iterative design-make-test-analyze cycles until a candidate with optimal drug properties emerges.
Accelerated Drug Discovery with XtalPi’s Technology
This includes the application of hundreds of autonomous robotic workstations that carry out parallel chemical synthesis and assays to generate real-world data at speed and scale, combined with AI models and quantum physics algorithms, to predict and authenticate novel drug candidates with greatly accelerated timeframes and reduced costs.
Expanding Partnerships in the Pharmaceutical Industry
XtalPi, which operates out of both China and the US, has announced similar discovery partnerships in recent months with Germany’s Merck KGaA (ETR: MRK) and Singapore’s Experimental Drug Development Centre (EDDC), further solidifying its position as a key player in the global AI-driven drug discovery space.-Fineline Info & Tech
